OncoSec Medical Incorporated (ONCS: OTCQB) | Vista Partners Updates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20


SAN FRANCISCO, CA–(Marketwired – May 6, 2015) – Vista Partners announced today that it has updated coverage on OncoSec Medical Inc. (OTCQB: ONCS) (“the Company”), a biopharmaceutical company developing DNA-based intratumoral cancer immunotherapies based in San Diego, CA, and maintains its twelve month price target of $1.20. Ross Silver, Principal Analyst at Vista Partners, stated, “There seems to be growing anticipation to learn when and if immunotherapy may become the standard of care for the treatment of certain types of cancer and potentially all types of cancer in the future. On April 29th, 2015, the FDA’s panel made a ruling on Amgen’s (AMGN) dual-acting cancer vaccine/viral therapy, talimogene laherparepvec (T-Vec) with a convincing 22-1 committee approval. Amgen is a one of the larger holdings in the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB). After T-Vec’s recent success and with what seems to be a growing trend in immunotherapy, one which is leaning towards utilizing electroporation based on the data ONCS has produced to date, the projected market value for Melanoma therapeutics is anticipated to reach $3.6 billion by 2020 according to MarketWatch.” Mr. Silver concludes, “ONCS entered into a clinical collaboration with the University of California, San Francisco (UCSF) in November, to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, and OncoSec’s ImmunoPulse (intratumoral IL-12) in metastatic melanoma. According to ONCS, recent data suggest that patients who are PD-L1 positive and have increased tumor-infiltrating lymphocytes (TILs) are more likely to respond to anti-PD-1/PD-L1 mAbs compared to patients who are PD-L1 negative. Therefore, therapies that promote TIL generation and PD-L1 positivity may play an important role in augmenting the clinical efficacy of these agents. According to ONCS, patients are expected to be enrolled within the next 60 days and enrollment is scheduled to be completed within 12 months.”

To download a FREE copy of the OncoSec Medical Inc. research report, please visit http://www.vistapglobal.com and click the “download research” icon to gain access to the report.

About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm’s professional staff has backgrounds in finance, corporate communications and investment banking. Vista focuses on investing globally across all market sectors. Vista also provides investment considerations on publicly traded companies through a platform of stock research reports, newsletters, company specific webpages and daily commentary. The platform of products is meant to serve as potential tools for investors to learn about investment considerations. It is Vista’s mission to provide investors with tools that may enable them to make profitable investment decisions with the goal to deliver investment considerations that outperform small, mid and large cap equity indexes.

Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more.

Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Copyright © 2015 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Source: otc markets